Stock events for Edwards Lifesciences Corp. (EW)
Over the past six months, Edwards Lifesciences' stock price has been influenced by several events, including a 17.26% increase between October 3, 2024, and October 2, 2025. In Q2 2025, Edwards Lifesciences reported strong results, with sales growing 11.9% to $1.53 billion and adjusted EPS at $0.67, leading to raised full-year guidance. Analyst ratings and price targets were adjusted by Stifel, Wells Fargo & Company, Barclays, Canaccord Genuity Group, JPMorgan Chase & Co., Evercore ISI, BTIG Research, and William Blair. Edwards Lifesciences announced a $500 million accelerated share repurchase program. The TAVR market experienced a slowdown, leading EW to revise its TAVR outlook for 2024 to +5-7% year-over-year growth.
Demand Seasonality affecting Edwards Lifesciences Corp.’s stock price
Explicit information regarding the demand seasonality for Edwards Lifesciences Corp.'s products and services is not readily available. The nature of medical device demand, particularly for critical cardiovascular conditions, may suggest less pronounced seasonality compared to consumer goods.
Overview of Edwards Lifesciences Corp.’s business
Edwards Lifesciences Corporation is a global medical technology company specializing in innovative solutions for advanced cardiovascular diseases, operating within the Health Technology sector, specifically in the Medical Specialties and Medical Instruments Manufacturing industries. The company is headquartered in Irvine, California, and its primary focus is on structural heart disease and critical care monitoring. Major products and technologies include Transcatheter Aortic Valve Replacement (TAVR) with the Edwards SAPIEN family of valves, Transcatheter Mitral and Tricuspid Therapies (TMTT) focusing on heart valve repair and replacement technologies, Surgical Structural Heart including surgical valve repair and replacement devices, and Critical Care, which was acquired by BD in 2024.
EW’s Geographic footprint
Edwards Lifesciences has a significant global presence with its global headquarters in Irvine, California. The company maintains manufacturing facilities in Draper, Utah; Costa Rica; the Dominican Republic; Puerto Rico; Singapore; and Limerick, Ireland. Edwards Lifesciences markets its products through a direct sales force and a network of independent distributors across North America, Europe, and Asia-Pacific. Geographically, the company generates revenue from the United States, Europe, Japan, and the Rest of World.
EW Corporate Image Assessment
There is no specific information detailing events that have negatively impacted Edwards Lifesciences Corp.'s brand reputation in the past year. The company is recognized for its patient-focused medical innovations and its strong performance, product innovation, and market leadership in structural heart technologies.
Ownership
Edwards Lifesciences is primarily owned by institutional shareholders, who hold approximately 85.49% of the company's stock, while retail investors own about 13.29%, and Edwards Lifesciences insiders hold 1.22%. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., JPMorgan Chase & Co, State Street Corp, and Wellington Management Group Llp. The largest individual shareholder is Michael A. Mussallem, who owns 4.45 million shares, representing 0.76% of the company.
Ask Our Expert AI Analyst
Price Chart
$73.36